Lupus & antiphospholipid syndrome
Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis
Authors' conclusion
In patients with LN, induction therapies of SOC with calcineurin inhibitors had the highest relative benefit achieving remission of LN.
Study context
- Population
- Patients (predominantly women) with active lupus nephritis (LN) in induction randomized clinical trials (RCTs)12 RCTs
- Comparison
- Triple immunosuppressive therapies vs standard of care (SOC) alone
- Outcome
- Primary renal remission (PRR) of LN
Pooled result
As reported in the abstract
PRR, direct pairwise comparisons vs SOC alone
Benefit ratio
- SOC+Tacrolimus
- 1.91 (95% CrI 1.45–2.56)
- SOC+Voclosporin
- 1.69 (95% CrI 1.30–2.23)
- SOC+Obinutuzumab
- 1.41 (95% CrI 1.09–1.84)
- SOC+Belimumab
- 1.32 (95% CrI 1.04–1.69)
Further pooled results
| Outcome | Benefit ratio (95% CrI) |
|---|---|
| PRR, indirect pairwise comparisonsSOC+Tacrolimus vs SOC+Rituximab · CrI | 2.30 (1.27–4.20) |
| PRR, indirect pairwise comparisonsSOC+Tacrolimus vs SOC+Anifrolumab · CrI | 1.98 (1.07–3.52) |
| PRR, indirect pairwise comparisonsSOC+Tacrolimus vs SOC+Ocrelizumab · CrI | 1.81 (1.12–2.82) |
| PRR, indirect pairwise comparisonsSOC+Tacrolimus vs SOC+Abatacept · CrI | 1.78 (1.07–2.91) |
| PRR, indirect pairwise comparisonsSOC+Voclosporin vs SOC+Rituximab · CrI | 2.03 (1.14–2.68) |
- Primary renal remission (PRR), indirect pairwise comparisons: 95% CrI
Ranking for PRR (SUCRA)
- SOC+Belimumab, SOC+Obinutuzumab, SOC+Voclosporin and SOC+Tacrolimus ranked as effective therapies inducing PRR, SUCRA probability scores
- between 61.14% and 95.12%
Safety
- Risk ratios of SAE and SIE not significantly different among the immunosuppressive therapies
Original publication
Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis. Lupus. Published 5 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →